Norman M Kneteman

Summary

Affiliation: University of Alberta
Country: Canada

Publications

  1. doi request reprint HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus
    Norman M Kneteman
    KMT Hepatech, Inc, Edmonton, Alberta, Canada
    Hepatology 49:745-52. 2009
  2. doi request reprint Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection
    Norman M Kneteman
    Division of Transplantation, Department of Surgery, University of Alberta, 8440 112 Street NW, Edmonton, AB, Canada
    Liver Transpl 18:38-44. 2012
  3. ncbi request reprint De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects
    Christian Toso
    Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
    Transplantation 83:1162-8. 2007
  4. ncbi request reprint Long-term graft function after allogeneic islet transplantation
    Jonathan R T Lakey
    Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
    Cell Transplant 16:441-6. 2007
  5. doi request reprint Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model
    Toshiyasu Kawahara
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Liver Transpl 16:974-82. 2010
  6. ncbi request reprint Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases
    Michele Molinari
    Department of Surgery, Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 5:2799-804. 2005
  7. ncbi request reprint The portal immunosuppressive storm: relevance to islet transplantation?
    A M James Shapiro
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Ther Drug Monit 27:35-7. 2005
  8. doi request reprint Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma
    Christian Toso
    Section of Hepatobiliary, Pancreatic, and Transplant Surgery, University of Alberta, Edmonton, Canada
    Liver Transpl 14:1107-15. 2008
  9. pmc The impact of sirolimus on hepatitis C recurrence after liver transplantation
    Sonal Asthana
    Department of Surgery, University of Alberta, Edmonton, Alberta
    Can J Gastroenterol 25:28-34. 2011
  10. doi request reprint The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma
    Shaheed Merani
    Department of Surgery, University of Alberta, Edmonton, Canada
    J Hepatol 55:814-9. 2011

Collaborators

Detail Information

Publications34

  1. doi request reprint HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus
    Norman M Kneteman
    KMT Hepatech, Inc, Edmonton, Alberta, Canada
    Hepatology 49:745-52. 2009
    ..These outcomes demonstrate the utility of the range of in vitro and in vivo models now available for anti-HCV drug development and support the potential utility of polymerase inhibitors in future combination therapies for HCV treatment...
  2. doi request reprint Impact of calcineurin inhibitors with or without interferon on hepatitis C virus titers in a chimeric mouse model of hepatitis C virus infection
    Norman M Kneteman
    Division of Transplantation, Department of Surgery, University of Alberta, 8440 112 Street NW, Edmonton, AB, Canada
    Liver Transpl 18:38-44. 2012
    ..7%) achieved a 1-log decline in the HCV titer (P = 1). Using this animal model, we could find no evidence supporting the routine use of CSA after LT in HCV-infected patients...
  3. ncbi request reprint De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects
    Christian Toso
    Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
    Transplantation 83:1162-8. 2007
    ..We report long-term outcomes and side effects after transplantation for hepatocellular carcinoma (HCC) using de novo, sirolimus-based immunosuppression (IS)...
  4. ncbi request reprint Long-term graft function after allogeneic islet transplantation
    Jonathan R T Lakey
    Clinical Islet Transplant Program, University of Alberta and Capital Health Authority, Edmonton, Alberta, Canada
    Cell Transplant 16:441-6. 2007
    ..In contrast, sustained insulin secretion with nearly normal HbA1c at 13 years follow-up was observed in another patient, providing hope for improving long-term graft outcomes for islet transplant recipient...
  5. doi request reprint Factors affecting hepatocyte isolation, engraftment, and replication in an in vivo model
    Toshiyasu Kawahara
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Liver Transpl 16:974-82. 2010
    ....
  6. ncbi request reprint Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases
    Michele Molinari
    Department of Surgery, Clinical Islet Transplant Program, University of Alberta, Edmonton, Alberta, Canada
    Am J Transplant 5:2799-804. 2005
    ..Our experience highlights an uncommon but potentially serious adverse effect of high-dose SRL in islet recipients...
  7. ncbi request reprint The portal immunosuppressive storm: relevance to islet transplantation?
    A M James Shapiro
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Ther Drug Monit 27:35-7. 2005
    ..This "portal storm" of immunosuppression may be relevant to intrahepatic islet transplantation...
  8. doi request reprint Total tumor volume predicts risk of recurrence following liver transplantation in patients with hepatocellular carcinoma
    Christian Toso
    Section of Hepatobiliary, Pancreatic, and Transplant Surgery, University of Alberta, Edmonton, Canada
    Liver Transpl 14:1107-15. 2008
    ....
  9. pmc The impact of sirolimus on hepatitis C recurrence after liver transplantation
    Sonal Asthana
    Department of Surgery, University of Alberta, Edmonton, Alberta
    Can J Gastroenterol 25:28-34. 2011
    ..While some immunosuppression strategies may accelerate hepatitis C virus (HCV) recurrence after liver transplantation (LT), the impact of sirolimus (SRL) is not known...
  10. doi request reprint The impact of waiting list alpha-fetoprotein changes on the outcome of liver transplant for hepatocellular carcinoma
    Shaheed Merani
    Department of Surgery, University of Alberta, Edmonton, Canada
    J Hepatol 55:814-9. 2011
    ..Liver transplantation is a recognized treatment for selected patients with hepatocellular carcinoma (HCC), but transplant criteria still need to be refined, especially in the case of more advanced or downstaged tumors...
  11. ncbi request reprint ABO-incompatible liver transplantation for critically ill adult patients
    Christian Toso
    Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
    Transpl Int 20:675-81. 2007
    ..Our results suggest that ABO-incompatible transplants should be viewed as an important therapeutic option in adult patients with acute liver failure awaiting an emergency procedure...
  12. doi request reprint Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the Scientific Registry of Transplant Recipients database
    Christian Toso
    Section of Hepatobiliary, Pancreatic, and Transplant Surgery, University of Alberta, Edmonton, Canada
    Hepatology 49:832-8. 2009
    ..A composite patient selection score combining TTV and AFP was the most effective of all tested staging criteria for the prediction of posttransplant patient survival for candidates with HCC...
  13. pmc Therapeutic efficacy of human hepatocyte transplantation in a SCID/uPA mouse model with inducible liver disease
    Donna N Douglas
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    PLoS ONE 5:e9209. 2010
    ..Thus, we reproduced the HSVtk (vTK)/GCV system of hepatic failure in SCID/uPA mice...
  14. doi request reprint Critical role of natural killer cells in the rejection of human hepatocytes after xenotransplantation into immunodeficient mice
    Toshiyasu Kawahara
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Transpl Int 23:934-43. 2010
    ..These results support a critical role for mouse NK cells in the rejection of human hepatocytes xenotransplanted to immunodeficient mice...
  15. doi request reprint Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma
    Christian Toso
    Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, Canada
    Hepatology 51:1237-43. 2010
    ..Conclusion: According to these data, sirolimus-based immunosuppression has unique posttransplant effects on HCC patients that lead to improved survival...
  16. ncbi request reprint Anti-HCV therapies in chimeric scid-Alb/uPA mice parallel outcomes in human clinical application
    Norman M Kneteman
    Department of Surgery, University of Alberta, Edmonton, Canada
    Hepatology 43:1346-53. 2006
    ..In conclusion, this system may help selection of lead compounds for advancement into human trials with an increased likelihood of clinical success while broadening the tools available for study of the biology of HCV infection...
  17. doi request reprint Additive effect of sirolimus and anti-death receptor 5 agonistic antibody against hepatocellular carcinoma
    Toshiyasu Kawahara
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Liver Int 33:1441-8. 2013
    ..The aim of this study was to evaluate the efficiency of a combined therapy of rapamycin (sirolimus) and anti-death receptor (DR)5 monoclonal antibody (mAb) on HCC...
  18. doi request reprint In vivo study of HCV in mice with chimeric human livers
    Norman M Kneteman
    Department of Surgery Faculty of Medicine and Oral Health Sciences, University of Alberta, Edmonton, Canada
    Methods Mol Biol 510:383-99. 2009
    ..This chapter reviews development, validation, and early application of a mouse model with a chimeric human liver...
  19. doi request reprint m-TOR inhibitors: what role in liver transplantation?
    Toshiyasu Kawahara
    Division of Transplantation, Department of Surgery, University of Alberta, Canada
    J Hepatol 55:1441-51. 2011
    ....
  20. doi request reprint The estimated number of patients with hepatocellular carcinoma selected for liver transplantation using expanded selection criteria
    Christian Toso
    Section of Hepatobiliary, Pancreatic and Transplant Surgery, University of Alberta, Edmonton, AB, Canada
    Transpl Int 22:869-75. 2009
    ..This data will assist Centers and policy agencies in predicting the need for resources linked to an expansion of criteria...
  21. ncbi request reprint Five-year follow-up after clinical islet transplantation
    Edmond A Ryan
    Department of Medicine, Clinical Islet Transplant Program, 2000 College Plaza, 8215 112th St, Edmonton, Alberta, Canada T6G 2C8
    Diabetes 54:2060-9. 2005
    ..The results, though promising, still point to the need for further progress in the availability of transplantable islets, improving islet engraftment, preserving islet function, and reducing toxic immunosuppression...
  22. ncbi request reprint Current status of islet cell transplantation
    Jose Oberholzer
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Adv Surg 37:253-82. 2003
  23. doi request reprint Human cytomegalovirus infection in humanized liver chimeric mice
    Toshiyasu Kawahara
    Division of Transplantation Surgery, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Hepatol Res 43:679-84. 2013
    ..In the current study, we describe the development of a mouse model that supports the in vivo propagation of HCMV...
  24. ncbi request reprint TRAIL inhibits tumor growth but is nontoxic to human hepatocytes in chimeric mice
    Chunhai Hao
    Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, Alberta, Canada
    Cancer Res 64:8502-6. 2004
    ..The results indicate that the recombinant soluble human TRAIL has a profound apoptotic effect on tumor cells but is nontoxic to human hepatocytes in vitro and in vivo...
  25. doi request reprint Arylacetamide deacetylase: a novel host factor with important roles in the lipolysis of cellular triacylglycerol stores, VLDL assembly and HCV production
    Mahra Nourbakhsh
    Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    J Hepatol 59:336-43. 2013
    ..We hypothesized that TG lipolysis and VLDL production are impaired during HCV infection so that these cellular processes can be diverted towards HCV production...
  26. ncbi request reprint Liver transplantation in severe hepatic trauma after hepatic artery embolization
    Ian B Anderson
    Department of Surgery and Critical Care, University of Calgary, Alberta, Canada
    J Trauma 58:848-51. 2005
  27. doi request reprint Targeted quantitative mass spectrometric identification of differentially expressed proteins between Bax-expressing and deficient colorectal carcinoma cells
    Peng Wang
    Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
    J Proteome Res 8:3403-14. 2009
    ..These results indicate the functional diversity of Bax and provide new research directions to study the biology of Bax-regulated apoptosis...
  28. doi request reprint Characterization of lipid and lipoprotein metabolism in primary human hepatocytes
    Ji Ling
    Group on the Molecular and Cell Biology of Lipids and Department of Biochemistry, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
    Biochim Biophys Acta 1831:387-97. 2013
    ..Further research needs to be done to maintain liver specific functions of primary human hepatocytes in prolonged cultures for these cells to be a viable model...
  29. ncbi request reprint Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma
    Norman M Kneteman
    Department of Surgery, Section of Hepatobiliary, Pancreatic and Transplantation Surgery, University of Alberta, Edmonton, Alberta T6G 2B7, Canada
    Liver Transpl 10:1301-11. 2004
    ..This sirolimus based immunosuppression protocol appears to have beneficial effects on tumor recurrence and survival with an acceptable rate of rejection and toxicity...
  30. ncbi request reprint Percutaneous transhepatic pancreatic islet cell transplantation in type 1 diabetes mellitus: radiologic aspects
    Richard J T Owen
    Departments of Diagnostic Imaging, University of Alberta Hospital, 8440 112th Street, Edmonton, Alberta, Canada T6G 2B7
    Radiology 229:165-70. 2003
    ..To report our experience with percutaneous transhepatic pancreatic islet cell transplantation in patients with type 1 diabetes mellitus...
  31. ncbi request reprint Liver trauma: management of devascularization injuries
    Ian B Anderson
    Department of Surgery and Trauma Services, University of Calgary, Calgary, Alberta, Canada
    J Trauma 57:1099-104. 2004
  32. doi request reprint Lipoprotein profiles in SCID/uPA mice transplanted with human hepatocytes become human-like and correlate with HCV infection success
    Rineke H G Steenbergen
    Department of Medical Microbiology and Immunology and Li Ka Shing Institute of Virology, Katz Centre for Pharmacy and Health Research, National Canadian Research Training Program in Hepatitis C, Centre de recherche du Centre Hospitalier de l Universite de Montreal, Hopital Saint Luc, Montreal, Quebec, Canada
    Am J Physiol Gastrointest Liver Physiol 299:G844-54. 2010
    ..Our data suggest that the weakest link in the HCV infection chain does not appear to be the presence of human hepatocytes per se. We believe that HCV infection also depends on the presence of sufficient levels of human lipoproteins...
  33. ncbi request reprint Defining optimal immunosuppression for islet transplantation based on reduced diabetogenicity in canine islet autografts
    A M James Shapiro
    Surgical Medical Research Institute, Department of Surgery, University of Alberta, Edmonton, Alberta, Canada
    Transplantation 74:1522-8. 2002
    ..We here explore the effects of clinically relevant doses of cyclosporine or tacrolimus when given alone or in combination with glucocorticoids on long-term canine islet autograft function...
  34. ncbi request reprint Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells
    Peng Wang
    Department of Laboratory Medicine and Pathology and Surgery, University of Alberta, Edmonton, Alberta, Canada
    Cell Signal 19:2237-46. 2007
    ..These studies therefore suggest that combination treatment with chemotherapy can overcome TRAIL resistance and enhance TRAIL therapeutic efficacy in treating pancreatic cancers...